Liraglutide

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2010 English Publisher:Springer Science and Business Media LLCJournal:Nature Reviews Drug Discovery, volume 9, pages 267-268 (issn: 1474-1776, eissn: 1474-1784,

Copyright policy )

Authors: Daniel J, Drucker; Argyris, Dritselis; Peter, Kirkpatrick;

doi: 10.1038/nrd3148

pmid: 20357801

Liraglutide

- Summary
- Subjects
- Metrics

Abstract

In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.

Related Organizations

Lunenfeld-Tanenbaum Research Institute
Canada
Mount Sinai Hospital
Canada

Keywords

Adult, United States Food and Drug Administration, Liraglutide, United States, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Drug Approval, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	177
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%